UNICORN Phase 2: Neoadjuvant Botensilimab Plus Balstilimab Shows Promising Activity in pMMR and dMMR Colon Cancer

Coverage, in order

1. 4d ago
   
   OncoDaily obscure study randomized trial

   UNICORN Phase 2: Neoadjuvant Botensilimab Plus Balstilimab Shows Promising Activity in pMMR and dMMR Colon Cancer

   Immunotherapy has transformed the treatment of mismatch repair-deficient (dMMR) colorectal cancer, but its role in proficient mismatch repair (pMMR) disease remains limited. While neoadjuvant immune checkpoint inhibition has demonstrated substantial

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.